{"groups":[{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"FG000","title":"Diffuse Large B Cell Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"FG001","title":"Classical Hodgkin Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"FG002","title":"Peripheral T Cell Lymphoma"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"30"},{"groupId":"FG002","numSubjects":"21"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"30"},{"groupId":"FG002","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}